Product Description
AVM0703 rapidly triggers the production and release of endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells (AVM-NKT). These supercharged immune cells have unique properties and appear rapidly in the blood following a single dose of AVM0703. They home to abnormal cells including cancer, infected cells and autoreactive lymphocytes. It is clear that these cells could play a significant role in addressing several serious conditions. The proprietary AVM0703 formulation is based on dexamethasone (DP), approved by the FDA at much lower doses since 1958. AVM0703 has been engineered to permit very high doses of dexamethasone to be administered without concerning side-effects. The unique, higher dose AVM0703 formulation is required to deploy activated AVM-NKT cells into the bloodstream for targeted delivery to abnormal cells. (Sourced from: https://avmbiotech.com/cancer/)
Mechanisms of Action: NK Cells
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AVM Biotechnology
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Acute Lymphoid Leukemia|Biphenotypic Acute Leukemia|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoproliferative Disorders|Mantle-Cell Lymphoma|T-Cell Leukemia|T-Cell Lymphoma
Phase 1: Acute Respiratory Distress Syndrome|COVID-19|Influenza, Human
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04366115 |
AVM0703 | P1 |
Not yet recruiting |
COVID-19|Influenza, Human|Acute Respiratory Distress Syndrome |
2031-12-01 |
50% |
2025-10-03 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
NCT04329728 |
OPAL | P2 |
Recruiting |
Mantle-Cell Lymphoma|Lymphoproliferative Disorders|Acute Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|T-Cell Lymphoma|Biphenotypic Acute Leukemia|T-Cell Leukemia|Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma |
2027-11-30 |
12% |
2026-04-16 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |